Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms.
APC
ATM
BRAF
ESR1
NF2
NOTCH1
RAS
TERT promoter
Columnar cell
Thyroid carcinoma
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
07
03
2024
accepted:
02
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
Columnar cell papillary thyroid carcinoma (CC-PTC) is a morphologic subtype of papillary thyroid carcinoma with a variable prognosis. It is characterized by neoplastic thyroid follicular-derived cells with pseudostratified columnar morphology arranged in papillary or follicular structures with supranuclear or subnuclear vacuoles. The molecular profile of this subtype has only recently come under scrutiny, with mixed results. The aim of this study is to further explore the morphologic, immunohistochemical, and genetic profile of CC-PTC, as well as to correlate these features with clinical outcomes. CC-PTC cases were identified from 3 institutions. Immunohistochemistry (ER, CDX2) and molecular testing (DNA and RNA sequencing) were performed. Clinicopathologic parameters and patient outcomes were recorded. Twelve cases (2006-2023) were identified, all in adults (age 45-91). Two presented with disease outside the thyroid gland (neck and mediastinum) and two presented with distant metastasis. Four were high-grade differentiated thyroid carcinomas (necrosis or mitoses), one of which died of disease. Four were noninvasive or minimally invasive, one of which locally recurred. Three patients had lymph node metastases. ER and CDX2 were positive in 73% and 50%, respectively. Pathogenic mutations were found in TERT promoter (n = 3), RAS (n = 2), ATM, NOTCH1, APC, and ESR1, along with cases bearing AGK::BRAF fusion (n = 1), BRAF VE1 expression (n = 1), and NF2 loss (n = 1). This study represents the largest molecularly defined cohort of non-oncocytic thyroid carcinomas with columnar cell morphology. These tumors represent a genetically and behaviorally heterogeneous group of neoplasms, some of which have RAS-like or follicular neoplasm-like genetics, some of which have BRAF-p.V600E-like or classic papillary thyroid carcinoma-like genetics, and some of which remain unclear. Noninvasive or minimally invasive tumors showed an indolent course compared to those with angioinvasion, gross extrathyroidal growth, or high-grade morphology. Consideration could be given to reclassification of this neoplasm outside of the subtyping of papillary thyroid carcinoma in light of its genetic diversity, distinct morphology, and clinical behavior more closely aligned with follicular thyroid neoplasms.
Sections du résumé
BACKGROUND
BACKGROUND
Columnar cell papillary thyroid carcinoma (CC-PTC) is a morphologic subtype of papillary thyroid carcinoma with a variable prognosis. It is characterized by neoplastic thyroid follicular-derived cells with pseudostratified columnar morphology arranged in papillary or follicular structures with supranuclear or subnuclear vacuoles. The molecular profile of this subtype has only recently come under scrutiny, with mixed results. The aim of this study is to further explore the morphologic, immunohistochemical, and genetic profile of CC-PTC, as well as to correlate these features with clinical outcomes.
METHODS
METHODS
CC-PTC cases were identified from 3 institutions. Immunohistochemistry (ER, CDX2) and molecular testing (DNA and RNA sequencing) were performed. Clinicopathologic parameters and patient outcomes were recorded.
RESULTS
RESULTS
Twelve cases (2006-2023) were identified, all in adults (age 45-91). Two presented with disease outside the thyroid gland (neck and mediastinum) and two presented with distant metastasis. Four were high-grade differentiated thyroid carcinomas (necrosis or mitoses), one of which died of disease. Four were noninvasive or minimally invasive, one of which locally recurred. Three patients had lymph node metastases. ER and CDX2 were positive in 73% and 50%, respectively. Pathogenic mutations were found in TERT promoter (n = 3), RAS (n = 2), ATM, NOTCH1, APC, and ESR1, along with cases bearing AGK::BRAF fusion (n = 1), BRAF VE1 expression (n = 1), and NF2 loss (n = 1).
CONCLUSIONS
CONCLUSIONS
This study represents the largest molecularly defined cohort of non-oncocytic thyroid carcinomas with columnar cell morphology. These tumors represent a genetically and behaviorally heterogeneous group of neoplasms, some of which have RAS-like or follicular neoplasm-like genetics, some of which have BRAF-p.V600E-like or classic papillary thyroid carcinoma-like genetics, and some of which remain unclear. Noninvasive or minimally invasive tumors showed an indolent course compared to those with angioinvasion, gross extrathyroidal growth, or high-grade morphology. Consideration could be given to reclassification of this neoplasm outside of the subtyping of papillary thyroid carcinoma in light of its genetic diversity, distinct morphology, and clinical behavior more closely aligned with follicular thyroid neoplasms.
Identifiants
pubmed: 38727854
doi: 10.1007/s12105-024-01645-2
pii: 10.1007/s12105-024-01645-2
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours [Internet]., 5th ed. International Agency for Research on Cancer., Lyon (France).
Evans HL (1986) Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 85:77–80. https://doi.org/10.1093/ajcp/85.1.77
doi: 10.1093/ajcp/85.1.77
pubmed: 3940424
Janovitz T, Williamson DFK, Wong KS et al (2021) Genomic profile of columnar cell variant of papillary thyroid carcinoma. Histopathology 79:491–498. https://doi.org/10.1111/his.14374
doi: 10.1111/his.14374
pubmed: 33783022
Sujoy V, Pinto A, Nosé V (2013) Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid 23:714–719. https://doi.org/10.1089/thy.2012.0455
doi: 10.1089/thy.2012.0455
pubmed: 23488912
Chen JH, Faquin WC, Lloyd RV, Nosé V (2011) Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol 24:739–749. https://doi.org/10.1038/modpathol.2011.2
doi: 10.1038/modpathol.2011.2
pubmed: 21358618
Barton CP, Brennan JA, Lowry TR, Russell MJ (2006) Columnar cell variant of papillary thyroid carcinoma. Ear Nose Throat J 85(640):643
pubmed: 17124931
Jiang C, Cheng T, Zheng X et al (2018) Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag Res 10:465–472. https://doi.org/10.2147/CMAR.S157823
doi: 10.2147/CMAR.S157823
pubmed: 29563836
pmcid: 5849916
Ylagan LR, Dehner LP, Huettner PC, Lu D (2004) Columnar cell variant of papillary thyroid carcinoma. Report of a case with cytologic findings. Acta Cytol 48:73–77. https://doi.org/10.1159/000326287
doi: 10.1159/000326287
pubmed: 14969185
Rottuntikarn W, Wangsiricharoen S, Rangdaeng S (2017) Cytomorphology and immunocytochemistry of columnar cell variant of papillary thyroid carcinoma. Cytopathology 28:338–341
doi: 10.1111/cyt.12429
pubmed: 28470960
Cho J, Shin JH, Hahn SY, Oh YL (2018) Columnar cell variant of papillary thyroid carcinoma: ultrasonographic and clinical differentiation between the indolent and aggressive types. Korean J Radiol 19:1000–1005. https://doi.org/10.3348/kjr.2018.19.5.1000
doi: 10.3348/kjr.2018.19.5.1000
pubmed: 30174490
pmcid: 6082763
Verma R, Paul P (2016) Columnar cell variant of papillary thyroid carcinoma: a diagnostic dilemma in fine-needle aspiration cytology. Diagn Cytopathol 44:816–819. https://doi.org/10.1002/dc.23517
doi: 10.1002/dc.23517
pubmed: 27279270
Jayaram G (2000) Cytology of columnar-cell variant of papillary thyroid carcinoma. Diagn Cytopathol 22:227–229. https://doi.org/10.1002/(SICI)1097-0339(200004)22:4%3c227::AID-DC5%3e3.0.CO;2-4
doi: 10.1002/(SICI)1097-0339(200004)22:4<227::AID-DC5>3.0.CO;2-4
pubmed: 10787142
Kini H, Pai RR, Kalpana S (2003) Solitary parotid metastasis from columnar cell carcinoma of the thyroid: a diagnostic dilemma. Diagn Cytopathol 28:72–75. https://doi.org/10.1002/dc.10226
doi: 10.1002/dc.10226
pubmed: 12561024
Gaertner EM, Davidson M, Wenig BM (1995) The columnar cell variant of thyroid papillary carcinoma. Case report and discussion of an unusually aggressive thyroid papillary carcinoma. Am J Surg Pathol 19:940–947. https://doi.org/10.1097/00000478-199508000-00010
doi: 10.1097/00000478-199508000-00010
pubmed: 7611541
Wenig BM, Thompson LDR, Adair CF et al (1998) Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer 82:740–753. https://doi.org/10.1002/(SICI)1097-0142(19980215)82:4%3c740::AID-CNCR18%3e3.0.CO;2-Y
doi: 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.0.CO;2-Y
pubmed: 9477108
Enriquez ML, Baloch ZW, Montone KT et al (2012) CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol 137:722–726. https://doi.org/10.1309/AJCPXE3PUBWVZCGZ
doi: 10.1309/AJCPXE3PUBWVZCGZ
pubmed: 22523209
Bongiovanni M, Mermod M, Canberk S et al (2017) Columnar cell variant of papillary thyroid carcinoma: cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer Cytopathol 125:389–397. https://doi.org/10.1002/cncy.21860
doi: 10.1002/cncy.21860
pubmed: 28374549
Garcia-Rendueles MER, Ricarte-Filho JC, Untch BR et al (2015) NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discov 5:1178–1193. https://doi.org/10.1158/2159-8290.CD-15-0330
doi: 10.1158/2159-8290.CD-15-0330
pubmed: 26359368
pmcid: 4642441
Guenter R, Patel Z, Chen H (2021) Notch signaling in thyroid cancer. Adv Exp Med Biol 1287:155–168. https://doi.org/10.1007/978-3-030-55031-8_10
doi: 10.1007/978-3-030-55031-8_10
pubmed: 33034031
pmcid: 8422843
https://www.ncbi.nlm.nih.gov/clinvar/variation/814/
Cracolici V, Cipriani NA (2023) High-grade non-anaplastic thyroid carcinomas of follicular cell origin: a review of poorly differentiated and high-grade differentiated carcinomas. Endocr Pathol 34:34–47
doi: 10.1007/s12022-023-09752-6
pubmed: 36692728
Zeng PYF, Prokopec SD, Lai SY et al (2024) The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep 43:113826. https://doi.org/10.1016/j.celrep.2024.113826
doi: 10.1016/j.celrep.2024.113826
pubmed: 38412093
pmcid: 11077417
Xu B, David J, Dogan S et al (2022) Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology 80:322–337. https://doi.org/10.1111/his.14550
doi: 10.1111/his.14550
pubmed: 34449926
Cracolici V, Ritterhouse LL, Segal JP et al (2020) Follicular thyroid neoplasms: comparison of clinicopathologic and molecular features of atypical adenomas and follicular thyroid carcinomas. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001489
doi: 10.1097/PAS.0000000000001489
pubmed: 32282345
Boyraz B, Sadow PM, Asa SL et al (2021) Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. Endocr Pathol 32:327–335. https://doi.org/10.1007/s12022-021-09683-0
doi: 10.1007/s12022-021-09683-0
pubmed: 34019236
pmcid: 9353615
Nikiforov YE, Seethala RR, Tallini G et al (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2:1023–1029. https://doi.org/10.1001/jamaoncol.2016.0386
doi: 10.1001/jamaoncol.2016.0386
pubmed: 27078145
pmcid: 5539411
Nikiforov YE, Baloch ZW, Hodak SP et al (2018) Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol 4:1125–1126
doi: 10.1001/jamaoncol.2018.1446
pubmed: 29902314
pmcid: 6584712
Chu Y-H, Sadow PM (2022) Kinase fusion-related thyroid carcinomas: towards predictive models for advanced actionable diagnostics. Endocr Pathol 33:421–435. https://doi.org/10.1007/s12022-022-09739-9
doi: 10.1007/s12022-022-09739-9
pubmed: 36308634
pmcid: 10283356
Chu Y-H, Sadow PM (2021) Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications. Diagn Histopathol (Oxf) 27:252–262. https://doi.org/10.1016/j.mpdhp.2021.03.003
doi: 10.1016/j.mpdhp.2021.03.003
pubmed: 34484420